Navigating Non-Compliance

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Gerald Treiman, IRB Chair John Stillman, IRB Director Maureen Brinkman, IRB Administrator Ann Johnson, IRB Administrator.
Safety Reporting IN Clinical Trials
UNANTICIPATED PROBLEMS INVOLVING RISKS TO SUBJECTS OR OTHERS & INCIDENTS OF NON-COMPLIANCE ( AKA PROTOCOL DEVIATIONS ) TRACY RIGHTMER, JD, CIP COMPLIANCE.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
1 © Huron Consulting Group Inc. All rights reserved. Huron is a management consulting firm and not a CPA firm, and does not provide attest services, audits,
Capturing and Reporting Adverse Events in Clinical Research
Director, Investigator Support & Integration Services, OCTRI
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Vanderbilt Human Research Protections Program
Defining Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Using the short form and reporting adverse events Erin Coons, Senior IRB Specialist, COMIRB 1.
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
Unanticipated Problems Potentially Involving Risks to Subjects or Others Research Protections Office Serving UVM and FAHC Updated April 2012.
New Adverse Event Reporting Policy Effective September 1, 2007.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
EMORY INSTITUTIONAL REVIEW BOARD VERSION Unanticipated Problems, Protocol Deviations and Non-Compliance.
Common Audit Findings UTHSC Institutional Review Board (IRB)
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Tough Love: Understanding the Purpose and Processes of Quality Assurance.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?
Office of Research Oversight 1 VHA Handbook Research Compliance Reporting Requirements Revised May 21, 2010 (Presentation prepared for HRPP 101,
JERI R. BARNEY, JD HRPP COMPLIANCE MANAGER YALE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM DECEMBER 13, 2012 Noncompliance.
AUDIT REQUIREMENTS, FINDINGS & BASICS RESEARCH COMPLIANCE.
1 Unanticipated problems Melody Lin, Ph.D. December,
Office of Research Oversight 1 VHA Handbook Research Compliance Reporting Requirements HRPP September
VHA Research Compliance Reporting Requirements ORD Accreditation Conference Call December 15, 2011.
Investigational Devices and Humanitarian Use Devices June 2007.
HRPP Policies & Forms Chapter Two Created/Revised for AAHRPP June 1, 2007.
Office of Research Oversight 1 Office of Research and Development Local Accountability Meeting January 2009.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
Role of Site Investigator Ensure subject safety is protected & well-managed Full compliance with requirements of Good Clinical Practice (GCP) Conduct the.
Non-compliance with Human Subjects Research Regulations J. Bruce Smith, MD, CIP November 2014 Continuing Education for IRB Members.
Doing IRB Right … Together JOHN POTTER, OD, MA Chair, Institutional Review Board.
GEORGIA STATE UNIVERSITY IRB ADAPTED FROM DHHS GUIDANCE ON UNANTICIPATED PROBLEMS Unanticipated Problems.
Main Line Hospitals Institutional Review Board Unanticipated Problems Anne Marie Hobson, BSN, JD, ORA Director Theresa Greaves, ORA Manager.
Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Unanticipated Problems 15 th FERCAP International Conference 24 Nov 15 Nagasaki, Japan.
Good Clinical Practice (GCP) and Monitoring Practices
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
Reportable Events Emory IRB 9/11/2014.
Risk Determinations and Research with Children
IRB reporting updates.
Reportable Events & Other IRB Updates February 2017
Adverse Event Reporting: Trials and Tribulations
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Bozeman Health Clinical Research
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
SERIOUS ADVERSE EVENTS REPORTING
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Multisite Human Subjects Research
This takes approximately 5 minutes or less from start to finish
Reportable Events & Revised Common Rule
IRB Reporting Requirements & Reportable New Information (RNIs)
Event Reporting in Human Subjects Research
Quality Assurance in Clinical Trials
Policy on Prompt Reporting
Common Rule
Protocol Approval Criteria
Research with Human Subjects
Presentation transcript:

Navigating Non-Compliance Angela Bain, IRB Administrator abain@uga.edu 706-542-3821

Reportable New Information (RNI) And RNI is how investigators report to the IRB the following situations that may occur in the conduct of their research: Unanticipated problem involving risks to subjects or others Adverse Events Protocol violations and deviations Each month we inform the committee of any RNIs that has been reported and reviewed since the previous meeting. Perhaps some of you have been wondering what these are and why we do this. What is an RNI? You may remember some of the policies that we have been passing over the past year. RNIs are one of those policies (these can all be found on the HSO website and in the Click IRB library)

Unanticipated problem involving risks to subjects or others Unexpected (in terms of nature, severity, or frequency) given the research procedures Related or possibly related to participation in research Suggests that the research places subjects or others at a greater risk of harm than was previously known or expected. Unanticipated problems involving risks to subjects or others include any incident, experience, or outcome that meets all of the following criteria:

Adverse Events Unexpected Adverse Event Nature, severity, or frequency is not consistent with the known foreseeable risks associated with the protocol Serious Adverse Event Results in death Is life threatening Requires hospitalization Results disability Results in congenital anomaly/birth defect An adverse event is any undesirable and unintended effect occurring as a result of interventions, interactions, or collection of identifiable private information in research. In biomedical research, any unfavorable medical occurrence in a human subject, including any abnormal sign, symptom, or disease, temporally associated with the subject’s participation in the research. Sometimes they are serious, usually they are unexpected.

Protocol Deviations Accidental or unintentional changes to, or non-compliance with the protocol that does not increase risk or decrease benefit; does not significantly affect subject’s rights, safety or welfare. Failure to collect an ancillary self-report questionnaire. Weighing a participant with shoes on. Vital signs obtained prior to informed consent. Performing a planned procedure on a different timetable than previously specified in the research protocol because of an unforeseen disruption such as a subject’s vacation. ICH GCP regulations indicate that the investigator should not implement any changes without agreement from the IRB, sponsor, etc – this is also what our policy says.

Protocol Violations Accidental or unintentional change to, or non-compliance with the IRB approved protocol that increases risk or decreases benefit, affects the subjects rights, safety, or welfare, or the integrity of the data: Inadequate informed consent Enrollment of subjects not meeting inclusion/exclusion criteria Improper breaking of the blinding of the study Inadequate record keeping Mishandled samples The FDA does not distinguish between a violation and a deviation – they consider all protocol variances to be violations. Any deviation not reported and later discovered in an audit is considered non-compliance with the FDA.

The Investigator submitted an RNI What now?

HSO Staff conducts a pre-review – If it is determined to not pose an increase of risk to participants, it is reviewed by the IRB Chair and designee. If it is determined to pose an increase of risk to participants, it is reviewed by the full committee. The committee will confirm whether risks to participants has been increased due to the event and will determine further action such as suspending, terminating, or modifying the research. The committee will also determine noncompliance. When these events are reviewed outside of the committee, our policy is to inform the committee of these actions, which is why you guys see these RNI reports each month.

When is it noncompliance? Noncompliance is defined as conducting research in a manner that violates federal law, state regulations, or institutional policies. Pretty much any protocol deviation or violation is considered to be noncompliance.

What does the IRB do? The IRB has the following determinations to make: Serious vs Non-Serious Continuing vs Non-Continuing

Non-Serious Noncompliance Minor or technical violations which result from inadvertent errors, inattention to detail, or failure to follow operational procedures which do not pose immediate risk to subjects, the environment, or researchers, and/or violate research subject’s rights and/or welfare

Serious Noncompliance Failure to adhere to the laws, regulations, or policies governing research that may reasonably be determined to: a. Involve substantive harm, or a genuine risk of substantive harm, to the safety, rights, or welfare of human or animal research subjects, research staff, or others. b. Result from deliberate disregard for the laws, regulations, or policies governing research that substantively compromise the effectiveness of the institution’s research oversight program

Continuing Noncompliance Persistent failure to adhere to the laws, regulations, or policies governing research and can represent either minor or serious noncompliance.